Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-77242113 in Healthy Japanese and Chinese Participants
NCT05062200Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icotrokinra in plaque psoriasis (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events up to 6 weeks and Plasma Concentration of JNJ-77242113. Started Oct 2021; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05062200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062200.